TY - JOUR
T1 - High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer
T2 - a retrospective study
AU - Takamizawa, Shigemasa
AU - Yazaki, Shu
AU - Kojima, Yuki
AU - Yoshida, Hiroshi
AU - Kitadai, Rui
AU - Nishikawa, Tadaaki
AU - Shimoi, Tatsunori
AU - Sudo, Kazuki
AU - Okuma, Hitomi Sumiyoshi
AU - Tanioka, Maki
AU - Noguchi, Emi
AU - Uno, Masaya
AU - Ishikawa, Mitsuya
AU - Kato, Tomoyasu
AU - Fujiwara, Yasuhiro
AU - Yonemori, Kan
N1 - Funding Information:
We thank all the patients whose data were used for the study. We thank Kyoko Onozawa for the secretarial assistance she provided. The National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan. Editage (Cactus Communications) provided editorial support in the form of medical writing, table assembly, and high-resolution image creation based on the authors’ detailed directions, collating author comments, copyediting, fact-checking, and referencing.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed in recent years; however, the available information on MSLN expression in cervical cancer is limited. This study aimed to evaluate MSLN expression in various histological types of cervical cancer and examine its relationship with prognosis. Methods: This retrospective study included patients with cervical cancer who underwent primary surgery between January 2000 and December 2020 at our institution. MSLN expression was evaluated by immunohistochemistry using clone SP74 and defined as positive if MSLN was expressed at any intensity. High MSLN expression was defined as an intensity of ≥ 2 + in ≥ 30% of tumour cells. The association between MSLN expression and clinicopathological factors was evaluated. Results: Overall, 123 patients were identified, and 140 tumour samples, including 17 paired primary and metastatic samples, were evaluated. Concerning histological type, 67 patients had squamous cell carcinoma (SCC), whereas 56 had non-SCC. MSLN expression was observed in 98.4% (121/123) of primary tumours. High MSLN expression was observed in 63.4% of samples (78/123), but it differed between the histological types (49.2% for SCC vs. 80.4% for non-SCC, p < 0.001). There was a significant correlation between MSLN expression in primary and metastatic lesions (Rs = 0.557, p = 0.015). In patients with common histological types, overall survival (OS) was shorter in the high MSLN expression group than in the low MSLN expression group (hazard ratio, 3.53; 95% confidence interval, 1.16–15.3, p = 0.03). Conclusions: MSLN was highly expressed in patients with cervical cancer, especially in those with non-SCC. High MSLN expression in the primary lesion was significantly associated with poor OS, and its expression was maintained in metastatic lesions. Our findings indicate that MSLN may be an attractive therapeutic target for cervical cancer. Trial registration: Retrospectivelyregistered. 2014-393.1
AB - Background: Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed in recent years; however, the available information on MSLN expression in cervical cancer is limited. This study aimed to evaluate MSLN expression in various histological types of cervical cancer and examine its relationship with prognosis. Methods: This retrospective study included patients with cervical cancer who underwent primary surgery between January 2000 and December 2020 at our institution. MSLN expression was evaluated by immunohistochemistry using clone SP74 and defined as positive if MSLN was expressed at any intensity. High MSLN expression was defined as an intensity of ≥ 2 + in ≥ 30% of tumour cells. The association between MSLN expression and clinicopathological factors was evaluated. Results: Overall, 123 patients were identified, and 140 tumour samples, including 17 paired primary and metastatic samples, were evaluated. Concerning histological type, 67 patients had squamous cell carcinoma (SCC), whereas 56 had non-SCC. MSLN expression was observed in 98.4% (121/123) of primary tumours. High MSLN expression was observed in 63.4% of samples (78/123), but it differed between the histological types (49.2% for SCC vs. 80.4% for non-SCC, p < 0.001). There was a significant correlation between MSLN expression in primary and metastatic lesions (Rs = 0.557, p = 0.015). In patients with common histological types, overall survival (OS) was shorter in the high MSLN expression group than in the low MSLN expression group (hazard ratio, 3.53; 95% confidence interval, 1.16–15.3, p = 0.03). Conclusions: MSLN was highly expressed in patients with cervical cancer, especially in those with non-SCC. High MSLN expression in the primary lesion was significantly associated with poor OS, and its expression was maintained in metastatic lesions. Our findings indicate that MSLN may be an attractive therapeutic target for cervical cancer. Trial registration: Retrospectivelyregistered. 2014-393.1
KW - Cervical cancer
KW - Mesothelin
KW - Squamous cell carcinoma
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85142514511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142514511&partnerID=8YFLogxK
U2 - 10.1186/s12885-022-10277-0
DO - 10.1186/s12885-022-10277-0
M3 - Article
C2 - 36434635
AN - SCOPUS:85142514511
SN - 1471-2407
VL - 22
JO - BMC cancer
JF - BMC cancer
IS - 1
M1 - 1215
ER -
